Litcius/Paper detail

Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study

Ute Spiekerkoetter, María L. Couce, Anibh M. Das, Corinne De Laet, Carlo Dionisi‐Vici, Allan M. Lund, Manuel Schiff, Marco Spada, Erik Sparve, Johan Szamosi, Roshni Vara, Mattias Rudebeck

2021The Lancet Diabetes & Endocrinology36 citationsDOI

Topics & Concepts

MedicineTerm (time)Internal medicinePhysicsQuantum mechanicsMetabolism and Genetic DisordersBiomedical Research and Pathophysiologymelanin and skin pigmentation
Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study | Litcius